摘要:目的: 觀察拉米夫定聯合阿德福韋酯治療E抗原陰性的慢性乙型肝炎患者的療效和安全性。 方法 :2006～2007年來我院就診的慢性乙型肝炎患者,給予拉米夫定100 mg/d,阿德福韋酯 100 mg/d,觀察治療前及治療后12、24 及48周谷丙轉氨酶水平、HBV DNA水平、乙型肝炎病毒血清標志物的應答效果及腎功能變化。 結果 :治療12周、24周和48周時,HBV DNA轉陰率分別為17%、43%和87%,且各組間差異具有統計學意義(P  lt;005);ALT復常率分別為13%,67%和100%,且各組間差異具有統計學意義(P  lt;005);治療48周時,所有患者均未發生表面抗原的消失;整個治療過程中,患者的耐受性良好,未發生一例嚴重不良事件。 結論 :拉米夫定聯合阿德福韋酯治療E抗原陰性的慢性乙肝患者,可獲得較好的臨床療效,該治療策略為臨床抗病毒治療提供了新的選擇。
Abstract: Objective: To observe the curative efficacy and safety of lamivudine combined with adefovir dipivoxil on HBeAgnegative initial treated chronic hepatitis B (CHB) patients. Methods : Outatients from our hospital between June, 2006 and August, 2007, who received lamivudine 100 mg and adefovir dipivoxil 10 mg per day were screened. And the level of ALT, HBV DNA, and urea nitrogen, as well as the statue of HBsAg and antiHBs were detected at week 12, 24, and 48 Results : The undetectable rates of HBV DNA were 17%, 43%, and 87% at week 12, 24, and 48 respectively, and the difference in response rate were statistic significantly (P lt;005). The ALT normalization rate were 13%, 67%, and 100% at week 12, 24, and 48 respectively, and the difference in response rate were statistic significantly (P lt;005); During the course of antiviral therapy, the loss of HBsAg was not observed and all patients were well tolerated. Conclusion : The combination of lamivudine and adefovir dipivoxil were effective for HBeAgnegative CHB patients, and this treatment strategy provided us a new option in clinical antiviral practice.

引用本文： 高志文,徐輝. 拉米夫定聯合阿德福韋酯治療E抗原陰性的慢性乙型肝炎患者療效分析. 華西醫學, 2009, 24(10): 2635-. doi: 復制